Top officials at Pfizer are assessing their strategy to improve the protection of Pfizer’s patents around the world. The results of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable protection of intellectual property arising agreement. The case describes how Pfizer transformed from an intellectual property law specialty to international trade of concern to the world through a close collaboration with the U.S. government helped the leaders … Read more »

Top officials at Pfizer are assessing their strategy to improve the protection of Pfizer’s patents around the world. The results of the Uruguay Round of the GATT negotiations is uncertain, and it is not clear whether an acceptable protection of intellectual property arising agreement. The case describes how Pfizer transformed intellectual property rights of a lawyer specialty into an international trade of concern to the world through a close collaboration with the U.S. government, leadership helped in the formation of a tripartite coalition among U.S., Japanese and European industry, the mobilization of the Pfizer organization. Indicates how far a company to protect its intellectual property in a world where the concept of intellectual property is not universally recognized or accepted. Can also be used to discuss the effectiveness and legitimacy of the Pfizer strategy, the conflicts between industrial and developing countries perspectives on international trade and national sovereignty, and the question of appropriate standards of intellectual property protection.
«Hide

from
Lynn Sharp Paine,
Michael A. Santoro
Source: Harvard Business School
27 pages.
Publication Date: Feb 13, 1992. Prod #: 392073-PDF-ENG
Pfizer: Global Protection of Intellectual Property HBR case solution

[related_post themes="flat"]